“Today is an important day for women’s health and I am proud that Italy is also part of it”. “Our aspiration is to be, here and now, for the health of every woman and her family and the community to which she belongs.is. But we also wish work alongside the institutions to be a sustainable partner for public health. “With these words Alper Alptekin, president and CEO of Organon Italia, greeted the birth of Organon, “the first global company that focuses on women’s health at every stage of life” which – reports a note – yesterday made its official debut on the New York Stock Exchange, with the sound of the bell by the company’s Executive leadership team and the commencement of stock exchanges.
“We want respond to the needs and requirements that impact the daily life of women and which inevitably – adds Alptekin – are reflected on the whole family and, therefore, on society. Officially we were born today, but we present ourselves in front of our interlocutors, be they institutional, scientific community and all people with health needs, with a consolidated experience and a history of great reputation and scientific value. Organon’s portfolio – he announces – will focus on three pillars: women’s health, biosimilars and products of established use. The diversification of our solutions is the engine that will fuel our growth, so that we can continue to invest in new therapeutic options and innovative solutions to respond to the most pressing health needs of women and their loved ones “, he stresses.
The numbers also tell the reality of Organon: over 140 markets, 6 production sites, a portfolio of over 64 products, 9 thousand employees in the world of which 1430 hired since February 2021. “In Italy we are among the top 25 pharmaceutical companies in the market – says CEO Alptekin – and we are in second place among companies with a portfolio in women’s health. Organon Italia is called to do its part, alongside women and the needs of each patient, but also to that of the institutions, to be a reference partner in promoting the sustainability of the National Health Service “, he concludes.
Listening to women and acting on their needs is the key to responding to the challenges of women’s health. With this goal, Organon launched the initiative ‘Wall of voices‘, a multimedia installation – reports the note – placed outside the New York stock exchange, which collects the voices of iconic women from all over the world working in favor of women. Organon Italia actively participated in the project, through the contribution of Maria Grazia Panunzi, president of the Italian Association of Women for Development (Aidos).
At launch, Organon’s portfolio is comprised of more than 60 treatments and products to be close to people around the world in more than 140 markets, with over 75% of its revenue ($ 6.5 billion) generated beyond outside the US. There are three pillars on which Organon’s value proposition is based: women’s health (with therapeutic solutions suitable for every stage of life: contraception, fertility, menopause); biosimilari (through a portfolio of biosimilar products in the oncology field); consolidated products (with therapeutic solutions of consolidated efficacy and sustainable value in the cardiovascular, hypercholesterolemia, respiratory, osteoarticular, osteoporosis and migraine fields).
Furthermore, Organon – the note continues – is characterized by a strong ‘female’ presence, both globally and in Italy. In our country it has 254 employees, almost half of which are women. Furthermore, the Leadership Team is made up of 60% women and the Board of Directors is female for 50% of its composition, an important result considering that the Italian average is 33%.